Every 10-Q that Acadia Pharmaceuticals Inc. (ACAD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ACAD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ACAD filings page.
ACADIA Pharmaceuticals reported modest revenue growth but sharply lower profit for the quarter ended March 31, 2026. Net product sales reached $268.1 million, up from $244.3 million a year earlier, driven by NUPLAZID at $166.9 million and DAYBUE at $101.2 million.
Despite higher sales, net income fell to $3.6 million from $19.0 million as selling, general and administrative expenses rose to $171.0 million, reflecting heavier commercial investment, while research and development spending remained roughly flat at $76.9 million. Cash, cash equivalents and investment securities totaled $851.5 million, and operating cash flow improved to $34.0 million, indicating the company is funding growth while maintaining a strong liquidity position.
ACADIA Pharmaceuticals reported higher profitability with growing product sales. Total revenue reached $278,633 (in thousands) for the quarter, up from $250,401 (in thousands) a year ago, driven by NUPLAZID at $177,530 and DAYBUE at $101,103 (each in thousands). Net income rose to $71,779 (in thousands), and diluted EPS was $0.42, reflecting stronger operations and a tax benefit.
Operating expenses were $242,877 (in thousands) as R&D increased to $87,829 and SG&A was $133,401 (each in thousands). Cost of product sales was $21,647 (in thousands), about 8% of net product sales. The effective tax rate was -61.0%, influenced by the One Big Beautiful Bill Act (OBBBA) and an accounting method change, boosting quarterly after‑tax results.
The balance sheet remained solid: cash and cash equivalents were $257,996 and investment securities were $589,023 (each in thousands). Stockholders’ equity improved to $917,272 (in thousands) from $732,793 at year‑end, supported by nine‑month operating cash flow of $158,567 (in thousands). Shares outstanding were 169,181,817 as of October 29, 2025.